Issue link: https://viewer.e-digitaledition.com/i/521055
RESEARCH FUELS WINTHROP-UNIVERSITY HOSPITAL'S LEADERSHIP ROLE IN CYBERKNIFE RADIOSURGERY WINTHROP-UNIVERSIT Y HOSPITAL'S COMPREHENSIVE academic research and clinical trials programs position its Division of Radiation Oncology to be a leader in the field. As a luminary teaching site at its main campus in Mineola, New York, Winthrop-University Hospital also provides the innovative training for CyberKnife radiosurgery to physicians from around the world. Jonathan Haas, MD, Chief of the Division of Radiation Oncology at Winthrop-University Hospital and Associate Professor of Radiation Oncology at Stony Brook University School of Medicine, has traveled extensively to present the latest radiation oncology research and to guide other facilities as new CyberKnife programs are established. Most recently, Dr. Haas made a CyberKnife radiosurgery presentation in Tokyo and assisted four hospitals in Japan with launching CyberKnife programs. He has also consulted with physicians from Brazil and Ukraine, who sought his guidance for best practices in prostate cancer treatment. Jonat ha n Ha a s, MD, Chief of the Division of Radiation Oncolog y at Winthrop-Universit y Hospita l a nd A sso ciate P rofessor of R ad iat ion Oncology at Stony Brook University School of Medicine. "The first attach- ment performs standard CyberKnife radiosurgery. The second attachment is a multileaf collimator [MLC] that enables the CyberKnife to treat additional cases that otherwise would require a standard linear accelerator. This allows us to treat the majority of tumors seen in our practice using the CyberKnife." Designed to improve the accuracy of radiation oncolog y t reat ments, the CyberKnife M6 Series provides unparalleled capabilities for treating cancers that respond well to radiation therapies. While the machine can treat tumors anywhere in the body, its ability to provide targeted stereotactic body radiation is its distinguishing feature. The M6 combines highly conformable beam shaping with real-time image guid- ance to lock on to a tumor and deliver highly fractionated radiation with sub- millimeter accuracy, killing tumor cells and sparing normal tissue. "This technology is a major advance- ment," Dr. Haas says. "CyberKnife's accuracy made it an excellent option for treating brain, lung, pancreatic and pros- tate cancers, and because of its continued evolution, we can expand the indications to treat more patients." The CyberKnife M6's accuracy is due, in part, to its six-jointed robotic arm that houses the MLC. The arm's broad range of motion allows physicians to deliver beams of radiation from the most effective angles. "The MLC consists of tungsten leaves that rapidly manipulate the radiation beam geometry into arbitrary apertures that actually conform to the shape of the target," Dr. Witten says. "We can deliver treatments so much more efficiently. A prostate treatment that might have taken 40 minutes to treat before, now takes 15–20 minutes, which definitely improves patient throughput." Jonathan Haas, MD, Chief of the Division of Radiation Oncology at Winthrop-University Hospital and Associate Professor of Radiation Oncology at Stony Brook University School of Medicine, consults with a patient in the new NYCyberKnife Center. "Patients previously traveled for CyberKnife treatment, but the new center makes the technology much more accessible. The NYCyberKnife Center fills a void for patients in the region and beyond who did not have the opportunity to receive CyberKnife radiosurgical treatment." — Jonathan Haas, MD, Chief of the Division of Radiation Oncology at Winthrop-University Hospital and Associate Professor of Radiation Oncology at Stony Brook University School of Medicine M D N E W S . CO M ■ MD NEWS Lower Hudson/Bronx | 7

